55% OS Boost in Urothelial Cancer with Enfortumab Vedotin + Pembrolizumab: Must-See ASCO Insights скачать в хорошем качестве

55% OS Boost in Urothelial Cancer with Enfortumab Vedotin + Pembrolizumab: Must-See ASCO Insights

Article: https://oncologytube.com/latest-asco-... Discover the latest ASCO 2025 genitourinary cancer updates from Dr. Nataliya Mar, MD, Assistant Professor of Hematology/Oncology at UC Irvine School of Medicine. Filmed at the MOASC Spotlight on Oncology event in Newport Beach on August 16, 2025, this interview covers breakthroughs in bladder, renal, and prostate cancers. Dr. Mar, a leading US genitourinary oncologist and Physician of Excellence (2021-2023), discusses ctDNA in the NIAGARA study, casdatifan with cabozantinib for RCC, and niraparib in the AMPLITUDE study. Watch for cutting-edge insights! 🔗 Learn more about Dr. Mar: https://www.ucihealth.org/clinicians/... 🔗 ASCO studies: https://asco.org 📌 Subscribe for more oncology updates: https://oncologytube.com/latest-asco-... #ASCO2025 #GenitourinaryCancer #Oncology #DrNataliyaMar #MOASC Timestamps: 00:00 - Intro: Dr. Nataliya Mar on ASCO 2025 Updates Dr. Nataliya Mar, a leading genitourinary oncologist, introduces the latest ASCO 2025 cancer advances at MOASC Spotlight. (References transcript: “Dr. Natalia Marr, one of the leading U.S. genito urinary oncologists at UCI Health... In this video, she'll discuss CT DNA, HIF2 alpha inhibitors, and nearoppa rib at Medical Oncology Association of Southern California Spotlight in Newport Beach.”) 00:15 - NIAGARA Study: ctDNA in Bladder Cancer Dr.izează: Mar discusses ctDNA’s role in muscle-invasive bladder cancer outcomes. (References transcript: “Niagara study which added tovalum to standard of care chemmotherapy... showed that patients who have not cleared their CT DNA post neoagjuvant treatment had worse outcomes compared to those who have.”) 01:05 - ARC-20 Study: Casdatifan & Cabozantinib in RCC Insights on the promising casdatifan-cabozantinib combo for clear cell renal cell carcinoma. (References transcript: “The combination of Kan and Kaboantinib seems to have promising activity in pretreated, locally advanced or metasthetic, clear cell, carcinoma... non-overlapping toxicities that are manageable.”) 02:00 - AMPLITUDE Study: Niraparib in Prostate Cancer Dr. Mar highlights niraparib’s impact in metastatic hormone-sensitive prostate cancer. (References transcript: “The amplitude study showed that adding the wrapperb to aberone versus placebo plus aberone, showed activity and a manageable toxicity profile... in patients with metastatic hormone sensitive prostate cancer.”) 02:30 - Closing: Impact of ASCO 2025 Cancer Advances Summary of key genitourinary oncology updates and Dr. Mar’s contributions. (References transcript: “So this meeting is always a wonderful opportunity to learn about interesting research and highlights research from the ESCO 2025 meeting.”) About OncologyTube.com: OncologyTube.com is a free video-sharing platform dedicated to oncology professionals, offering cancer research updates through videos, audio, PowerPoint presentations, and more. Visit OncologyTube.com for a detailed web post on this and many other cancer topics and oncology insights. Follow OncologyTube: eNewsletter: https://oncologytube.com/newsletter/ Twitter:   / oncologytube   LinkedIn:   / oncologytube-com   Facebook:   / oncologytube   Instagram:   / oncologytube   YouTube:    / oncologytube   Connect with Us: Share your thoughts in the comments! Join the discussion.